Skin rash is the most common target-related toxicity of EGFR antibodies, occurred in 42% of patients, lower than previously reported rates for EGFR/HER3 bispecific antibodies (14, 15) and cetuximab (80%–86%; refs. 16, 17). This evidence concerns the gene ERBB3 and Skin rash.